openPR Logo
Press release

Artificial Pancreas Market Analysis, Segments and Value Chain Till 2020

01-19-2017 05:06 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: SA-BRC

Artificial Pancreas Market Analysis, Segments and Value Chain

CDC and WHO statistics suggest over 100,000 new cases of Type 1 diabetes occur among teenagers and young adults over the world every year. Globally there are around 347 million people with diabetes of which around 35 million suffer from Type 1 diabetes with an estimated 1.5 million living in United States. The growth in Type 1 diabetes is pegged at around 3%-5% increase in incidence every year. Artificial pancreas is an automated insulin pump that monitors glucose level continuously and release insulin accordingly to keep the level constant. Thus, these devices in essence are not new technology but simply a union of two existing diabetes technologies i.e. continuous glucose monitoring and insulin pumps. These devices are the result of refinement and advancement of insulin pumps, continuous glucose monitors along with sophistication of electronics that have become smaller, accurate to micro-levels and miniaturized. In Type 1 diabetes, there is complete absence in creation of insulin and patients have to otherwise constantly juggle monitoring of blood glucose and administering insulin. Manual attention loses perception over a period of time and delays in administering insulin cost dearly to patients. In a person without diabetes, the beta cells in the pancreas make enough insulin, a hormone that helps convert food into energy. They detect blood glucose levels and deliver insulin based on those levels with little risk of the glucose levels ever going dangerously high or low. Artificial pancreas eliminates the need for paying attention to the monitoring and dosage. Once planted on the body they constantly monitor the blood glucose and deliver insulin as needed which frees the patient completely from this task, giving them time for pursuing their routine.

Free Sample Report@ http://www.sa-brc.com/Global-Artificial-Pancreas-Market-Assessment--Forecast-2016---2020/up12

Ongoing SA-BRC research estimates suggest that the US$ 16 billion dollar diabetes care market is split between Type 1 diabetes care that is critical and valued at approximately US$ 5.5 billion in 2014 and Type 2 diabetes care occupying the rest. The market is all set to expand with the introduction of these devices and Medtronic Inc, Dexcom Inc and Johnson & Johnson are currently the leaders in this market. J&J's diabetes division, Animas, launched its latest combo device Animas Vibe in 2014 in Canada. Medtronic claims to have capitalized the US market with the approval of its MiniMed 530G. Tandem Diabetes Care is a focused company with another product t:slim pump, which is also set to be adopted by patients. These devices that deliver both insulin and glucagon can create artificial mimicry that is very close to organic pancreas. In 2011, the FDA began seeking public opinions on creating a regulatory draft on approval of these devices, and with current progress and public acceptance it is expected that Medtronic and J&J who are both seeking an FDA approval for their devices will have a smooth entry into the North American market.

Click For Request TOC@ http://www.sa-brc.com/Global-Artificial-Pancreas-Market-Assessment--Forecast-2016---2020/upcomingdetail12

Other internal substitutes such as inhalable insulin Afrezza by MannKind is also a considerable competition to existing and incoming devices. Europe leads the way with the largest market for artificial pancreas, followed by North America. Europe's early approvals have paved the way for market growth. The stringent FDA guidelines and device approval procedures along with the reimbursement regulations have taken a toll on the launch. The devices are expected to gain traction in North America after gaining approvals from 2014-2016. Asia-Pacific countries such as China & India having very large diabetic population will present excellent revenue opportunities for players in coming years. Many experts show concern from a business perspective that device cost and size of target population is still not clearly remunerating the years of research and development along with financial investment put in these technologies till now. This being said, the over 7% growth of insulin delivery devices for past decade is a clear indicator for a market ready to absorb new technology.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Artificial Pancreas Market Analysis, Segments and Value Chain Till 2020 here

News-ID: 417329 • Views: 543

More Releases from SA-BRC

Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-202 …
Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage. Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine
Companion Diagnostics Market Share, Trends Analysis: 2017-2021
Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The

All 5 Releases


More Releases for Artificial

Artificial Turf Market – Global Need Assumptions 2025 | Artificial Lawn, Grass …
Global Artificial Turf Market: Snapshot Growth opportunities abound in the global market for artificial turf as residential and commercial property owners increasingly focus on ways of keeping lawns green even during the rising incidences of draughts across the globe. Along with providing an easy way of conserving the water otherwise spent on keeping natural grass alive, artificial grass, or artificial turf as it is often referred to, helps eliminate the need
Artificial Blood Market Development
Artificial Blood Market Potential According to the World Health Organization (WHO), there are around 50,000 stem cell transplantations performed annually worldwide, which include 2,000 cord blood hematopoietic stem cell transplants performed each year. Use of stem cells from cord blood is increasing, as it does not require perfect human leukocyte antigen (HLA) tissue matching, can be used allogenically, and has less incidence of graft v/s host disease. According to the New
Artificial intelligence for industrial microbiology
Munich, Germany, November 23, 2017 - vermicon AG, the specialist for microbiological solutions, is launching the new Scan VIT® system for analysis of microorganisms. It is able to quantify and specifically identify single cells directly and without time-consuming enrichment steps. A fully automated analysis evaluation is provided by the intelligent VIT® Vision software, which is the centerpiece of the new, patented technology. In contrast to conventional rapid test methods, the
Artificial Blood Market
Artificial blood is an artificially developed substitute for red blood cells. For decades, scientists have been trying to develop artificial blood from various sources and through different methods to address the shortage of blood for transfusions. Inadequate number of blood donors and the criticality of blood-type rejection have encouraged researchers to develop artificial blood, thus reducing the dependency on blood donors. Transfusion of red blood cells (RBCs) is a standard
Artificial Blood Market
Artificial blood is an artificially developed substitute for red blood cells.  For decades, scientists have been trying to develop artificial blood from various sources and through different methods to address the shortage of blood for transfusions. Inadequate number of blood donors and the criticality of blood-type rejection have encouraged researchers to develop artificial blood, thus reducing the dependency on blood donors. Transfusion of red blood cells (RBCs) is a standard and
Global Artificial Intelligence Market
According to a new report, Global Artificial Intelligence Market (2016-2022), published by KBV Research, the global artificial intelligence market is estimated to reach USD 16,274.0 Million by 2022, at a CAGR of 44.5% from 2016 to 2022. The North America market dominated the Global Artificial Intelligence Market in 2015, and would continue to be a dominant market till 2022; thereby growing at a CAGR of 42.7% during the forecast period.